治疗诱导和先前存在的Anti-peg抗体:流行率,临床影响和未来前景
Sherif A Gaballa1, Taro Shimizu2, Hidenori Ando3
1Department of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University; 1-78-1 Sho-machi, Tokushima 770-8505, Japan; Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Minia University, 61519 Minia, Egypt.
聚乙烯糖醇 (PEG) 化增强了药物的疗效,但可以触发免疫反应. 既存在的,又诱导的抗PEG抗体会导致加速清除和不良反应,因此需要对抗体进行查和针对PEGylated疗法的新策略.
科学领域:
- 生物材料科学 生物材料科学
- 免疫学 免疫学 免疫学
- 制药科学 制药科学
背景情况:
- 聚乙烯甘醇 (PEG) 在制药,化品和家用产品中广泛使用.
- 基化,即PEG与分子的结合,提高了治疗循环时间和疗效.
- 然而,PEGylation可以引起免疫反应,导致抗PEG抗体.
研究的目的:
- 研究PEG免疫性和抗原性在临床应用中所带来的挑战.
- 突出抗PEG抗体对PEG化治疗药物的疗效和安全性的影响.
- 强调需要策略来缓解对PEGylated药物的免疫反应.
主要方法:
- 审查关于PEGylation,免疫性和临床应用的现有研究.
- 对抗PEG抗体影响PEG化治疗药物的机制的分析.
- 讨论临床影响,包括加速血液清理和伪过敏反应.
主要成果:
- 常见的是抗PEG抗体,它们都是由治疗诱导的,并且在健康个体中已经存在.
- 这些抗体与PEGylated治疗药物结合,激活补体系统.
- 这导致加速血液清理 (ABC) 和与补充激活相关的伪过敏反应 (CARPA).
结论:
- 对于PEG化疗法来说,PEG免疫性是一个重大挑战.
- 美国FDA等监管机构建议对抗PEG抗体进行查.
- 开发克服PEG免疫性策略对于推进PEG化药物递送系统至关重要.
更多相关视频
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
06:07Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood
Published on: February 5, 2020
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
Microorganisms in Medicine and Therapeutics
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
